drugset / Trial / NCT00296465

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Three Dosage Strengths of Pulsatile GnRH

NCT00296465

Phase 2/3 Completed 132 enrolled Ferring Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will be performed in approximately 132 women with anovulatory/oligoovulatory infertility.

Timeline

Start
2005-02
Primary completion
2005-11
Completion
2005-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Clomiphene Other / unclassified Oral
Subject Lutrepulse Unknown 5 ug Intravenous
Subject Lutrepulse Unknown 10 ug Intravenous
Subject Lutrepulse Unknown 20 ug Intravenous

Indications